EP11.02-06 Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS

IPSOS (NCT03191786) is the first global, multicenter, open-label, randomised Phase III study to show that, in patients with NSCLC ineligible for platinum-doublet chemotherapy (PDC), atezolizumab significantly improved OS vs single-agent chemotherapy in the intention-to-treat (ITT) population (stratified HR, 0.78; 95% CI: 0.63, 0.97; P=0.028; median follow-up, 41.0 months). A consistent benefit was shown across key subgroups, including subgroups according to PD-L1 expression, and no new or unexpected safety concerns were observed.